MedTrace Logo

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

NCT03680417 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 590

Last updated 2019-09-12

No results posted yet for this study

Summary

to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants

Conditions

  • Safety Issues
  • Immunogenicity

Interventions

BIOLOGICAL

Measles-Rubella (MR) Vaccine

Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.

Sponsors & Collaborators

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Dominicus Husada, Dr · Child Health Dept. Dr. Soetomo Hospital/School of Medicine, Airlangga Univ.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
9 Months
Max Age
47 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-16
Primary Completion
2018-02-26
Completion
2018-08-01

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03680417 on ClinicalTrials.gov